3S Pharmaceutical Group China

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Zhao Peng
Senior BD Manager 

abbisko China

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.
Website:
abbisko.com
Company Size (Fulltime employees)
Please specify your partnering goal
no
Headquartner in China
xiaoyi wu
BDAD 

AnHeart Therapeutics China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua  Zheng
Dr Lihua Zheng
LinkedIn logo CBO & co-Founder 
Functionality
Dr. Weiqing Wang
Associate Director of BD 
Functionality
Dr. Akira Liu
Director of BD 
Functionality

Ansun Biopharma United States

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.
Company Size (Fulltime employees)
Please specify your partnering goal
BD
Headquartner in China
Max Wang
BD 

Bayer China

Pharma
Website:
Www.bayer.com
Partnering Objectives
Headquartner in China
Cheryl Yang
BD AD 

Bayer Healthcare China

Bayer Healthcare
Dr. Min Pang
Alliance Manager 

BeiGene China

A Biopharma company, looking for license in opportunities.
Website:
Www.BeiGene.com
Company Size (Fulltime employees)
Year of foundation
10
Please specify your partnering goal
Partner
Headquartner in China
Ms. Yan Liu
Vice president 
Functionality

Beijing Continent Pharmaceutical Co., Ltd. China

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Qin Li
Associate Director,Business Development 

BioPegasus, LLC United States

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Website:
not available
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
1) Seeking investment(s) for developing cost-effective and minimally invasive blood antibody biomarker tests for Alzheimer’s disease diagnosis and early detection (a 3-year project); and/or 2) Looking for any interested party(ies) to work together.
Headquartner in China
Assets Information 1
biomarker and target discovery technology platform|||
Biotech/Pharma Asset Stage
Your Research Tool and Service name
A unique and transformative λ phage cDNA expression library construction and screening (not phage display). A cost-effective and robust novel biomarker and target discovery technology platform for novel diagnostic and therapeutic development.
Service Description
BioPegasus' technology platform provides a revolutionary tool for systematically and thoroughly studying novel molecular interactions and mechanism of actions with any molecule of interest and allowing unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time in novel diagnostic and therapeutic development.
Target client type
1) As diagnostic and early detection tests for Alzheimer's disease: general population for early detection (POCT, age 50 years and better) and patients for severity and diagnosis (lab tests); 2) As a research tool: client types include research institutions and diagnostic IVD, biotech and pharma companies
Slides Deck
(pdf, 957.61KB)
Dr. Tianlin Ma
Founder 
Functionality

Biosion Inc., China

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.
Company Size (Fulltime employees)
Year of foundation
2013
Please specify your partnering goal
Seeking partners in big pharma or established biotech companies to co-develop or license assets from Biosion's pipeline or to explore new collaborations for innovative antibody discovery by using our proprietary H³ antibody discovery platform and SynAb™ technology. We are also seeking additional investment to support advancement of our innovative antibody pipeline move into the clinic.
Headquartner in China
Assets Information 1
BSI-045B|TSLP: High affinity superior humanized antibody for the treatment of asthma and atopic dermatitis (Ex-China global rights)|Severe Asthma|Pending
Assets Information 2
BSI-03802|CD40: Humanized antibody molecule with superior agonist activity (Ex-China global rights)|solid cancer|Pending
Assets Information 3
BSI-001|HER2: hu5G9, best-in-class efficacy partner of trastuzumab and for next generation HER2 ADC development|HER2+ cancer|PCT
Biotech/Pharma Asset Stage
Dr. Mingjiu Chen
CEO 
Functionality